WuXi Biologics (Cayman) Inc. (HKG:2269)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Biologics	16.51B	16.03B	15.00B	-	-
Biologics Growth	2.97%	6.85%	-	-	-
Xdc	4.05B	2.12B	990.42M	-	-
Xdc Growth	90.80%	114.44%	-	-	-
Adjustments and Eliminations	-1.89B	-1.12B	-726.52M	-	-
Biotechnology	-	-	-	10.29B	5.61B
Biotechnology Growth	-	-	-	83.35%	40.88%
Total	18.68B	17.03B	15.27B	10.29B	5.61B
Total Growth	9.63%	11.56%	48.38%	83.35%	40.88%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
North America	10.70B	8.07B	8.50B	5.23B	2.48B
North America Growth	32.48%	-4.98%	62.49%	110.91%	15.98%
Europe	4.32B	5.14B	2.55B	2.28B	446.60M
Europe Growth	-15.91%	101.90%	11.86%	409.68%	43.39%
People's Republic of China (PRC)	2.82B	3.12B	3.72B	2.51B	2.46B
People's Republic of China (PRC) Growth	-9.65%	-16.07%	48.13%	1.89%	75.06%
Rest of The World	836.35M	698.48M	507.08M	274.18M	222.51M
Rest of The World Growth	19.74%	37.75%	84.94%	23.22%	75.07%
Total	18.68B	17.03B	15.27B	10.29B	5.61B
Total Growth	9.63%	11.56%	48.38%	83.35%	40.88%

Source: S&P Global Market Intelligence.